• Convertible bonds bearing interest at an annual rate of 7.9% plus a non-conversion premium of 0.1% and not accompanied by any guarantee
• Objective: development of new connected medical devices and marketing of devices in new countries
Issoire, January 2, 2023, 7:30 a.m. CET – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacture of medical devices and injectable drug delivery systems, announces the issue of convertible bonds under a contract entered into on December 30, 2022 with three funds managed by the management company Vatel Capital.
Eric Dessertenne, CEO of BIOCORP, declares: “This issue, carried out in the same spirit as the previous issues of convertible bonds for the benefit of funds managed by Vatel Capital and now fully repaid, represents for BIOCORP an interesting opportunity to increase our financing capacities while controlling the associated dilutive risk. This is in line with what we were able to announce at the end of the past year and are delighted to be able to allocate new resources to the strong development of BIOCORP. »